Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial.

@article{Cesne2005PhaseIS,
  title={Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial.},
  author={Axel le Cesne and Jean-Yves Blay and Ian Judson and A. T. Van Oosterom and Jaap Verweij and John Radford and Paul C. Lorigan and Sjoerd Rodenhuis and Isabelle Laure Ray-Coquard and Sylvie Bonvalot and Françoise Collin and J. L. Jimeno and Eugenio Donato di Paola and M van Glabbeke and Ole Steen Nielsen},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2005},
  volume={23 3},
  pages={576-84}
}
PURPOSE This nonrandomized multicenter phase II study was performed to evaluate the activity and safety of Ecteinascidin (ET-743) administered at a dose of 1.5 mg/m(2) as a 24-hour continuous infusion every 3 weeks in patients with pretreated advanced soft tissue sarcoma. PATIENTS AND METHODS Patients with documented progressive advanced soft tissue sarcoma received ET-743 as second- or third-line chemotherapy. Antitumor activity was evaluated every 6 weeks until progression, excessive… CONTINUE READING

Citations

Publications citing this paper.

References

Publications referenced by this paper.
Showing 1-10 of 37 references

Metastatic soft tissue sarcoma in adults: Prognosis and treatment options

O Nielsen, JY Blay, IR Judson
Am J Cancer 2:211-221, • 2003

Soft tissue sarcomas of adults: state of the translational science.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2003

A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2002

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

G Demetri, M Von Mehren, CD Blanke
N Engl J Med • 2002

Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2002

Similar Papers

Loading similar papers…